Dose escalation of antipsychotic drugs in schizophrenia: A meta-analysis of randomized controlled trials

Schizophrenia Research

Volumn 166, Issue 1-3, 2015, Pages 187-193

  Dold, Markus ^a   Fugger, Gernot ^a   Aigner, Martin ^b   Lanzenberger, Rupert ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b General Hospital Tulln   (Austria)

Author keywords

Antipsychotic drugs; High dose treatment; Non response; Schizophrenia; Treatment resistance

Indexed keywords

FLUPHENAZINE; HALOPERIDOL; QUETIAPINE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; DRUG DOSE ESCALATION; DRUG EFFICACY; HUMAN; META ANALYSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; DRUG ADMINISTRATION;

ANTIPSYCHOTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84955385439     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.04.024     Document Type: Article

References (30)

1. Adesola A., Anozie I., Erohubie P., James B. Prevalence and correlates of "high dose" antipsychotic prescribing: findings from a hospital audit. Ann. Med. Health Sci. Res. 2013, 3:62-66.
2. Baldessarini R.J., Cohen B.M., Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 1988, 45:79-91.
3. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
4. Bondolfi G., Baumann P., Dufour H. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. Eur. Neuropsychopharmacol. 1996, 6(Suppl. 2):S21-S25.
5. Borenstein M., Hedges L., Higgins J., Rothstein H. Comprehensive Meta-Analysis, Version 2 2006, Biostat, Englewood, NY.
6. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
7. Cohen J. Statistical Power Analysis for the Behavioural Sciences 1969, Academic Press, New York.
8. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophr. Bull. 1997, 23:663-674.
9. Davis J.M., Chen N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 2004, 24:192-208.
10. Dold M., Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid. Based Ment. Health 2014, 17:33-37.
11. Dold M., Samara M.T., Li C., Tardy M., Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst. Rev. 2015, CD009831.
12. Egger M., Davey S., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
13. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167:686-693.
14. Goff D.C., McEvoy J.P., Citrome L., Mech A.W., Bustillo J.R., Gil R., Buckley P., Manschreck T.C., Achtyes E.D., Macklin E.A. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J. Clin. Psychopharmacol. 2013, 33:485-490.
15. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Thibaut F., Moller H.J. World federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J. Biol. Psychiatry 2012, 13:318-378.
16. Hiemke C., Baumann P., Bergemann N., Conca A., Dietmaier O., Egberts K., Fric M., Gerlach M., Greiner C., Grunder G., Haen E., Havemann-Reinecke U., Jaquenoud Sirot E., Kirchherr H., Laux G., Lutz U.C., Messer T., Muller M.J., Pfuhlmann B., Rambeck B., Riederer P., Schoppek B., Stingl J., Uhr M., Ulrich S., Waschgler R., Zernig G. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011, 44:195-235.
17. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration 2011, [updated March 2011], (available from www.cochrane-handbook.org).
18. Honer W.G., MacEwan G.W., Gendron A., Stip E., Labelle A., Williams R., Eriksson H., Group S.S. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 2012, 73:13-20.
19. Huf W., Kalcher K., Pail G., Friedrich M.E., Filzmoser P., Kasper S. Meta-analysis: fact or fiction? How to interpret meta-analyses. World J. Biol. Psychiatry 2011, 12:188-200.
20. Kasper S., Tauscher J., Willeit M., Stamenkovic M., Neumeister A., Küfferle B., Barnas C., Stastny J., Praschak-Rieder N., Pezawas L., de Zwaan M., Quiner S., Pirker W., Asenbaum S., Podreka I., Brücke T. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J. Biol. Psychiatry 2002, 3:133-146.
21. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
22. Kinon B.J., Kane J.M., Johns C., Perovich R., Ismi M., Koreen A., Weiden P. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol. Bull. 1993, 29:309-314.
23. Klemm E., Grunwald F., Kasper S., Menzel C., Broich K., Danos P., Reichmann K., Krappel C., Rieker O., Briele B., Hotze A.L., Möller H.J., Biersack H.J. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am. J. Psychiatry 1996, 153:183-190.
24. Latimer E.A., Naidu A., Moodie E.E., Clark R.E., Malla A.K., Tamblyn R., Wynant W. Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals. Psychiatr. Serv. 2014, 65:1210-1217.
25. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161(2 Suppl.):1-56.
26. Lindenmayer J.P., Citrome L., Khan A., Kaushik S., Kaushik S. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J. Clin. Psychopharmacol. 2011, 31:160-168.
27. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 1991, 48:739-745.
28. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
29. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:790-812.
30. The Cochrane Collaboration Review Manager (RevMan) [Computer program]. Version 5.3 2014, The Nordic Cochrane Centre, Copenhagen.